724 related articles for article (PubMed ID: 37450923)
21. MYC needs MNT.
Link JM; Hurlin PJ
Cell Cycle; 2013 Feb; 12(3):385-6. PubMed ID: 23324353
[No Abstract] [Full Text] [Related]
22. Low molecular weight inhibitors of Myc-Max interaction and function.
Yin X; Giap C; Lazo JS; Prochownik EV
Oncogene; 2003 Sep; 22(40):6151-9. PubMed ID: 13679853
[TBL] [Abstract][Full Text] [Related]
23. MYC on the path to cancer.
Dang CV
Cell; 2012 Mar; 149(1):22-35. PubMed ID: 22464321
[TBL] [Abstract][Full Text] [Related]
24. The Mad side of the Max network: antagonizing the function of Myc and more.
Rottmann S; Lüscher B
Curr Top Microbiol Immunol; 2006; 302():63-122. PubMed ID: 16620026
[TBL] [Abstract][Full Text] [Related]
25. The c-MYC oncoprotein as a treatment target in cancer and other disorders of cell growth.
Pelengaris S; Khan M
Expert Opin Ther Targets; 2003 Oct; 7(5):623-42. PubMed ID: 14498825
[TBL] [Abstract][Full Text] [Related]
26. Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis.
Diolaiti D; McFerrin L; Carroll PA; Eisenman RN
Biochim Biophys Acta; 2015 May; 1849(5):484-500. PubMed ID: 24857747
[TBL] [Abstract][Full Text] [Related]
27. Differential effects by Mad and Max on transformation by cellular and viral oncoproteins.
Cerni C; Bousset K; Seelos C; Burkhardt H; Henriksson M; Lüscher B
Oncogene; 1995 Aug; 11(3):587-96. PubMed ID: 7630643
[TBL] [Abstract][Full Text] [Related]
28. The Myc/Max/Mad network and the transcriptional control of cell behavior.
Grandori C; Cowley SM; James LP; Eisenman RN
Annu Rev Cell Dev Biol; 2000; 16():653-99. PubMed ID: 11031250
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT.
Zhang Z; Sun H; Dai H; Walsh RM; Imakura M; Schelter J; Burchard J; Dai X; Chang AN; Diaz RL; Marszalek JR; Bartz SR; Carleton M; Cleary MA; Linsley PS; Grandori C
Cell Cycle; 2009 Sep; 8(17):2756-68. PubMed ID: 19652553
[TBL] [Abstract][Full Text] [Related]
30. Targeting miR-21 with NL101 blocks c-Myc/Mxd1 loop and inhibits the growth of B cell lymphoma.
Li S; He X; Gan Y; Zhang J; Gao F; Lin L; Qiu X; Yu T; Zhang X; Chen P; Tong J; Qian W; Xu Y
Theranostics; 2021; 11(7):3439-3451. PubMed ID: 33537096
[No Abstract] [Full Text] [Related]
31. Analysis of Myc/Max/Mad network members in adipogenesis: inhibition of the proliferative burst and differentiation by ectopically expressed Mad1.
Pulverer B; Sommer A; McArthur GA; Eisenman RN; Lüscher B
J Cell Physiol; 2000 Jun; 183(3):399-410. PubMed ID: 10797315
[TBL] [Abstract][Full Text] [Related]
32. Function and regulation of the transcription factors of the Myc/Max/Mad network.
Lüscher B
Gene; 2001 Oct; 277(1-2):1-14. PubMed ID: 11602341
[TBL] [Abstract][Full Text] [Related]
33. Visualization of Myc/Max/Mad family dimers and the competition for dimerization in living cells.
Grinberg AV; Hu CD; Kerppola TK
Mol Cell Biol; 2004 May; 24(10):4294-308. PubMed ID: 15121849
[TBL] [Abstract][Full Text] [Related]
34. Expression of the myc-family proto-oncogenes and related genes max and mad in synovial tissue.
Roivainen A; Pirilä L; Yli-Jama T; Laaksonen H; Toivanen P
Scand J Rheumatol; 1999; 28(5):314-8. PubMed ID: 10568429
[TBL] [Abstract][Full Text] [Related]
35. The activities of MYC, MNT and the MAX-interactome in lymphocyte proliferation and oncogenesis.
Link JM; Hurlin PJ
Biochim Biophys Acta; 2015 May; 1849(5):554-62. PubMed ID: 24731854
[TBL] [Abstract][Full Text] [Related]
36. Loss of the Max-interacting protein Mnt in mice results in decreased viability, defective embryonic growth and craniofacial defects: relevance to Miller-Dieker syndrome.
Toyo-oka K; Hirotsune S; Gambello MJ; Zhou ZQ; Olson L; Rosenfeld MG; Eisenman R; Hurlin P; Wynshaw-Boris A
Hum Mol Genet; 2004 May; 13(10):1057-67. PubMed ID: 15028671
[TBL] [Abstract][Full Text] [Related]
37. Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis.
Nguyen HV; Vandenberg CJ; Ng AP; Robati MR; Anstee NS; Rimes J; Hawkins ED; Cory S
Blood; 2020 Mar; 135(13):1019-1031. PubMed ID: 31978211
[TBL] [Abstract][Full Text] [Related]
38. Drosophila Myc: A master regulator of cellular performance.
Grifoni D; Bellosta P
Biochim Biophys Acta; 2015 May; 1849(5):570-81. PubMed ID: 25010747
[TBL] [Abstract][Full Text] [Related]
39. Dynamic in vivo interactions among Myc network members.
Yin X; Landay MF; Han W; Levitan ES; Watkins SC; Levenson RM; Farkas DL; Prochownik EV
Oncogene; 2001 Aug; 20(34):4650-64. PubMed ID: 11498788
[TBL] [Abstract][Full Text] [Related]
40. Mnt: a novel Max-interacting protein and Myc antagonist.
Hurlin PJ; Qúeva C; Eisenman RN
Curr Top Microbiol Immunol; 1997; 224():115-21. PubMed ID: 9308234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
